Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All paxlovid studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchPaxlovidPaxlovid (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

All Studies   All Outcomes    Recent:   

The Paxlovid Rebound Study: A Prospective Cohort Study to Evaluate Viral and Symptom Rebound Differences Between Paxlovid and Untreated COVID-19 Participants

Pandit et al., medRxiv, doi:10.1101/2022.11.14.22282195
Nov 2022  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Recovery 1% Improvement Relative Risk Viral clearance 3% Symptomatic rebound -171% Viral rebound -52% Paxlovid for COVID-19  Pandit et al.  EARLY TREATMENT Is early treatment with paxlovid beneficial for COVID-19? Prospective study of 170 patients in the USA (Aug - Nov 2022) No significant difference in outcomes seen c19early.org Pandit et al., medRxiv, November 2022 Favorspaxlovid Favorscontrol 0 0.5 1 1.5 2+
Prospective study of 170 COVID-19 patients in the USA, showing no significant difference in symptomatic and viral recovery times, and higher risk of symptomatic rebound, without statistical significance. There were more elderly patients in the paxlovid group.
5 paxlovid patients did not test negative during the 16 day daily followup, compared to zero for control. Only patients testing negative or reporting no symptoms were included in the recovery time analyses. KM curves show no significant difference in viral or symptomatic recovery.
risk of no recovery, 1.2% lower, RR 0.99, p = 0.90.
risk of no viral clearance, 2.9% lower, RR 0.97, p = 0.73.
symptomatic rebound, 170.9% higher, RR 2.71, p = 0.06, treatment 24 of 127 (18.9%), control 3 of 43 (7.0%).
viral rebound, 52.4% higher, RR 1.52, p = 0.41, treatment 18 of 127 (14.2%), control 4 of 43 (9.3%).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Pandit et al., 15 Nov 2022, prospective, USA, preprint, 8 authors, study period 4 August, 2022 - 1 November, 2022. Contact: jpandit@scripps.edu.
This PaperPaxlovidAll
The Paxlovid Rebound Study: A Prospective Cohort Study to Evaluate Viral and Symptom Rebound Differences Between Paxlovid and Untreated COVID-19 Participants
MD Jay A Pandit, Jennifer M Radin, Danielle Chiang, Emily Spencer, Jeff Pawelek, Mira Diwan, Leila Roumani, Michael Mina
doi:10.1101/2022.11.14.22282195
Introduction: The uptake of Paxlovid in individuals infected with COVID-19 has been significantly limited by concerns around the Paxlovid rebound phenomenon despite the scarcity of evidence around its epidemiology. The purpose of this study was to prospectively compare the epidemiology of Paxlovid rebound in treated and untreated participants with acute COVID-19 infection Methods: We designed a decentralized, digital, prospective observational study in which participants who tested positive for COVID-19 using eMed Test-to-Treat telehealth kits and were clinically eligible for Paxlovid were recruited to be evaluated for viral and symptom clearance, as well as rebound. Participants were assigned to a Paxlovid or control group based on their decision to take Paxlovid. Following initial diagnosis based on a telehealth proctored test both groups were provided 12 telehealth proctored rapid antigen home tests and asked to test on a regular frequent schedule for 16 days and answer symptom surveys. Viral rebound based on test results and COVID-19 symptom rebound based on patient reported symptoms were evaluated. Results: Viral rebound incidence was 14.2% in the Paxlovid group (n=127) and 9.3% in the control group (n=43). COVID-19 symptom rebound incidence was higher in the Paxlovid group (18.9%) compared to the control group (7.0%). There were no notable differences in viral rebound by age, gender, pre-existing conditions, or major symptom groups during the acute phase or at the 1-month interval. Conclusion: This preliminary report of our prospective study suggests that rebound after clearance of test positivity or symptom resolution is higher than previously reported. However, we observed a similar rate of rebound in both in the Paxlovid and control groups. Large studies with diverse participants and extended follow-up are needed to better understand the rebound phenomena.
References
Alshanqeeti, Bhargava, COVID-19 Rebound After Paxlovid Treatment: A Case Series and Review of Literature, Cureus
Anderson, Caubel, Rusnak, Investigators, Nirmatrelvir-Ritonavir and Viral Load Rebound in Covid-19, N Engl J Med
Callaway, COVID rebound is surprisingly common -even without Paxlovid, Nature
Carlin, Clark, Chaillon, Garretson, Bray et al., Virologic and Immunologic Characterization of COVID-19 Recrudescence after Nirmatrelvir/Ritonavir Treatment, Res Sq
Cdc, COVID-19 Rebound After Paxlovid Treatment: The Centers for Disease Control and Prevention
Charness, Gupta, Stack, Strymish, Lindy, Rebound of SARS-CoV-2 Infection after Nirmatrelvir-Ritonavir Treatment, N Engl J Med
Coulson, Adams, Gray, Evans, COVID-19 "Rebound" associated with nirmatrelvir/ritonavir pre-hospital therapy, J Infect
Deo, Choudhary, Moser, Ritz, Daar et al., Viral and Symptom Rebound in Untreated COVID-19 Infection
Dong, Du, Gardner, An interactive web-based dashboard to track COVID-19 in real time, Lancet Infect Dis
Farley, FDA Updates on Paxlovid for Health Care Providers, U.S. Food & Drug Administration
Ganatra, Dani, Ahmad, Kumar, Shah et al., Oral Nirmatrelvir and Ritonavir in Non-hospitalized Vaccinated Patients with Covid-19, Clin Infect Dis
Hammond, Leister-Tebbe, Gardner, Abreu, Wisemandle, Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19, N Engl J Med
Harris, Taylor, Minor, Elliott, Fernandez et al., The REDCap consortium: Building an international community of software platform partners, J Biomed Inform
Harris, Taylor, Thielke, Payne, Gonzalez et al., Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support, J Biomed Inform
Peluso, Anglin, Durstenfeld, Martin, Kelly et al., Effect of Oral Nirmatrelvir on Long COVID Symptoms: 4 Cases and Rationale for Systematic Studies, Pathog Immun
Pfizer, Pfizer To Provide, Government with an Additional 10 Million Treatment Courses of its Oral Therapy to Help Combat COVID-19
Rubin, From Positive to Negative to Positive Again-The Mystery of Why COVID-19
Smith, Li, Moser, Yeh, Currier et al., Recurrence of Symptoms Following a 2-Day Symptom Free Period in Patients With COVID-19, JAMA Netw Open
Wang, Berger, Davis, Kaelber, Volkow et al., COVID-19 rebound after Paxlovid and Molnupiravir during January
Wang, Chen, Zhao, Feng, Rapid COVID-19 rebound in a severe COVID-19 patient during 20-day course of Paxlovid, J Infect
Wang, Volkow, Davis, Berger, Kaelber et al., COVID-19 rebound after Paxlovid treatment during, Omicron BA
Xie, Choi, Al-Aly, Nirmatrelvir and the Risk of Post-Acute Sequelae of COVID-19, medRxiv
{ 'institution': [{'name': 'medRxiv'}], 'indexed': { 'date-parts': [[2022, 11, 16]], 'date-time': '2022-11-16T05:52:36Z', 'timestamp': 1668577956421}, 'posted': {'date-parts': [[2022, 11, 15]]}, 'group-title': 'Infectious Diseases (except HIV/AIDS)', 'reference-count': 0, 'publisher': 'Cold Spring Harbor Laboratory', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'accepted': {'date-parts': [[2022, 11, 15]]}, 'abstract': '<jats:p>Introduction: The uptake of Paxlovid in individuals infected with COVID-19 has been ' 'significantly limited by concerns around the Paxlovid rebound phenomenon despite the scarcity ' 'of evidence around its epidemiology. The purpose of this study was to prospectively compare ' 'the epidemiology of Paxlovid rebound in treated and untreated participants with acute ' 'COVID-19 infection Methods: We designed a digital, prospective observational study, which ' 'included participants who tested positive for COVID-19 and were clinically eligible for ' 'Paxlovid. Participants were assigned to a Paxlovid or control group based on their decision ' 'to take the medication. Both groups were provided 12 rapid antigen tests and asked to test ' 'and answer symptom surveys on a regular frequent schedule for 16 days. Viral rebound based on ' 'test results and COVID-19 symptom rebound based on patient reported symptoms were evaluated. ' 'Results: Viral rebound incidence was 14.2% in the Paxlovid group (n=127) and 9.3% in the ' 'control group (n=43). COVID-19 symptom rebound incidence was higher in the Paxlovid group ' '(18.9%) compared to the control group (7.0%). There were no notable differences in viral ' 'rebound by age, gender, pre-existing conditions, or major symptom groups during the acute ' 'phase or at the 1-month interval. Conclusion: This preliminary report of our prospective ' 'study suggests that rebound after clearance of test positivity or symptom resolution is ' 'higher than previously reported. However, we observed a similar rate of rebound in both in ' 'the Paxlovid and control groups. Large studies with diverse participants and extended ' 'follow-up are needed to better understand the rebound phenomena.</jats:p>', 'DOI': '10.1101/2022.11.14.22282195', 'type': 'posted-content', 'created': { 'date-parts': [[2022, 11, 15]], 'date-time': '2022-11-15T18:49:34Z', 'timestamp': 1668538174000}, 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'The Paxlovid Rebound Study: A Prospective Cohort Study to Evaluate Viral and Symptom Rebound ' 'Differences Between Paxlovid and Untreated COVID-19 Participants', 'prefix': '10.1101', 'author': [ { 'ORCID': 'http://orcid.org/0000-0003-0119-0881', 'authenticated-orcid': False, 'given': 'Jay A', 'family': 'Pandit', 'sequence': 'first', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0003-3843-0842', 'authenticated-orcid': False, 'given': 'Jennifer M', 'family': 'Radin', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0003-0919-9303', 'authenticated-orcid': False, 'given': 'Danielle', 'family': 'Chiang', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0003-2650-4357', 'authenticated-orcid': False, 'given': 'Emily G', 'family': 'Spencer', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0003-1419-6131', 'authenticated-orcid': False, 'given': 'Jeff B', 'family': 'Pawelek', 'sequence': 'additional', 'affiliation': []}, {'given': 'Mira', 'family': 'Diwan', 'sequence': 'additional', 'affiliation': []}, {'given': 'Leila', 'family': 'Roumani', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-0674-5762', 'authenticated-orcid': False, 'given': 'Michael J', 'family': 'Mina', 'sequence': 'additional', 'affiliation': []}], 'member': '246', 'container-title': [], 'original-title': [], 'link': [ { 'URL': 'https://syndication.highwire.org/content/doi/10.1101/2022.11.14.22282195', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 11, 15]], 'date-time': '2022-11-15T18:49:34Z', 'timestamp': 1668538174000}, 'score': 1, 'resource': {'primary': {'URL': 'http://medrxiv.org/lookup/doi/10.1101/2022.11.14.22282195'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022, 11, 15]]}, 'references-count': 0, 'URL': 'http://dx.doi.org/10.1101/2022.11.14.22282195', 'relation': {}, 'published': {'date-parts': [[2022, 11, 15]]}, 'subtype': 'preprint'}
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit